Company Profile
Natera Stock Price, News & Analysis
- Ticker:
- NTRA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
258.03 USD (-1.51%)
Close
Last updated: July 27, 2026
30.5B USD
Market cap
Why the stock is moving
As of Jul 27, 2026, NTRA closed down 1.51% at $258.03. No new same-company headline was identified in the current news window.
Company overview
Business overview
Natera is a molecular diagnostics company focused on cell-free DNA testing across oncology, women's health, and organ health.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Natera sits in precision diagnostics rather than therapeutics.
Business Model Characteristics
The business is driven by test volume, reimbursement, and the expansion of its oncology and reproductive-testing franchises.
Position Within the Biotechnology Landscape
Natera occupies a top-tier diagnostics niche because its platform can scale across multiple clinical use cases.
Future catalysts
Natera’s catalysts are Signatera reimbursement, Prospera adoption, and continued MRD-platform penetration. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSK · Source: GSK plc
- 02
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
LEGN · Source: Legend Biotech Corporation
- 03
- 04
- 05
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
KYMR · Source: Kymera
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Natera (NTRA)?
Natera (NTRA) most recently closed at 258.03 USD, a -1.51% move versus the previous session.
What is the market cap of Natera (NTRA)?
Natera currently has a market capitalization of 30.5B USD on BioPharmSignal.
What does Natera do?
Natera is a molecular diagnostics company focused on cell-free DNA testing across oncology, women's health, and organ health.
On which exchange is NTRA stock listed?
Natera (NTRA) is associated with NASDAQ, United States, Biopharma.
What is Natera?
Natera’s catalysts are Signatera reimbursement, Prospera adoption, and continued MRD-platform penetration.
Which conditions is Natera targeting with Natera?
Natera is associated with oncology based on its company overview and current catalyst commentary.
How does Natera describe recent progress with Natera?
Natera’s catalysts are Signatera reimbursement, Prospera adoption, and continued MRD-platform penetration.
What is Signatera?
Natera’s catalysts are Signatera reimbursement, Prospera adoption, and continued MRD-platform penetration.